Please ensure Javascript is enabled for purposes of website accessibility

Why Oncocyte Shot 13% Higher Today

By Eric Volkman - Feb 5, 2021 at 6:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The announcement of a new share issue usually drives a stock's price down, after all.

What happened

Cancer diagnostics specialist Oncocyte (OCX -8.86%) rose at a double-digit pace on Friday on news that it's tapping the stock market for a new round of capital-raising.

So what

Oncocyte priced its previously announced underwritten secondary stock issue of 7.78 million shares at $4.50 apiece. If all goes well, this should bring in gross proceeds of roughly $35 million. The underwriters have a 30-day option to buy nearly 1.17 million additional shares at the offering price. The issue should close on or about Tuesday, Feb. 9.

Closeup of an IV drip.

Image source: Getty Images.

New share flotations tend to make investors nervous, as they are dilutive.

However, in this case the impact of the incoming stock will be relatively light. Fewer than 9 million shares in total are being floated, while Oncocyte currently has over 428 million shares outstanding.

Also, the company is being very purposeful about this flotation. It says it intends to use its share of the proceeds to market and develop testing products aimed at identifying the most appropriate treatments for cancer patients. The money could also be utilized for more acquisitions of complementary assets, such as its recently announced purchase of the key assets of peer diagnostics specialist Chronix Biomedical.

Now what

The combination of a relatively low-impact share issue and Oncocyte's solid reasons for floating it have clearly inspired confidence. On Thursday, the healthcare stock closed 13% higher at $6 per share. This is well above the new issue's pricing, so investors are obviously excited about the company's prospects.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

OncoCyte Corporation Stock Quote
OncoCyte Corporation
OCX
$0.98 (-8.86%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
334%
 
S&P 500 Returns
117%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.